Trexquant Investment’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Trexquant Investment’s Portfolio EIGR Stock Details EIGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-602	Closed	-$94K	–	1823
2021 Q4	$94K	Buy	+602	New	+$116K	0.01%	1238
2020 Q3	–	Sell	-1,114	Closed	-$321K	–	1600
2020 Q2	$321K	Buy	+1,114	New	+$328K	0.02%	848
2019 Q1	–	Sell	-785	Closed	-$239K	–	1385
2018 Q4	$239K	Buy	+785	New	+$254K	0.01%	857

Other funds holding EIGR

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Trexquant Investment's EIGR Position: Q1 2022 in Review

Trexquant Investment sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q1 2022, closing a stake of 602 shares — an estimated $94K sold.

Trexquant Investment first reported a position in EIGR in Q4 2018 and held it in 3 quarters. The position peaked at $321K in Q2 2020. 94 funds tracked by Wall St. Rank hold EIGR as of Q1 2022.

Trexquant Investment reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q1 2022 after selling out during the quarter.
Trexquant Investment sold 602 Eiger BioPharmaceuticals, Inc. shares in Q1 2022, an estimated $94K.
Trexquant Investment first reported a position in Eiger BioPharmaceuticals, Inc. in Q4 2018 and held it in 3 quarters.
Trexquant Investment's Eiger BioPharmaceuticals, Inc. position peaked at $321K in Q2 2020.
94 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q1 2022.

Based on Trexquant Investment's 13F filing for Q1 2022, filed 13 May 2022.